Compare GD & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GD | MRNA |
|---|---|---|
| Founded | 2019 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.6B | 91.2B |
| IPO Year | 2007 | 2018 |
| Metric | GD | MRNA |
|---|---|---|
| Price | $358.42 | $215.86 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 24 | 23 |
| Target Price | ★ $419.29 | $158.47 |
| AVG Volume (30 Days) | 1.2M | ★ 12.9M |
| Earning Date | 10-30-2026 | 11-06-2026 |
| Dividend Yield | ★ 1.75% | N/A |
| EPS Growth | 13.35 | ★ 21.77 |
| EPS | ★ 15.45 | N/A |
| Revenue | ★ $52,550,000,000.00 | $19,263,000,000.00 |
| Revenue This Year | $8.21 | $24.04 |
| Revenue Next Year | $5.25 | $10.79 |
| P/E Ratio | $23.48 | ★ N/A |
| Revenue Growth | ★ 10.13 | 4.29 |
| 52 Week Low | $306.77 | $22.28 |
| 52 Week High | $400.00 | $280.80 |
| Indicator | GD | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 51.92 | 47.11 |
| Support Level | $337.39 | $181.02 |
| Resistance Level | $360.12 | $254.48 |
| Average True Range (ATR) | 9.08 | 17.19 |
| MACD | -0.46 | -3.89 |
| Stochastic Oscillator | 27.42 | 16.00 |
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments are aerospace, marine, combat systems, and technologies. General Dynamics' aerospace segment manufactures Gulfstream business jets and operates a global aircraft servicing operation. Combat systems produces land-based combat vehicles such as the M1 Abrams tank and Stryker armored personnel carrier, as well as munitions. The marine segment builds and services nuclear submarines, destroyers, and support ships. The technologies segment contains two main units: an IT business that primarily serves the government market and a mission systems business focusing on electronics that provide command, control, computing, intelligence, surveillance, and reconnaissance capabilities to the military.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.